Randomized Trialhigh evidence
First clinical demonstration of sustained insulin-like growth factor 1 elevation via oral somatostatin receptor 5 antagonism: a phase 1 trial of SCO-240.
European journal of endocrinology·April 30, 2026·PMID 42097580
Why it mattersCurrent GH deficiency treatment requires daily injections. An oral agent that stimulates endogenous GH could reduce treatment burden and offer a more physiologic replacement. This first-in-human data establishes target engagement and safety, supporting further development.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled